Connected With Latham

10

In each episode of Connected With Latham, we discuss ideas, developments, and trends shaping the global economy.

Recent Episodes
  • Episode 98 – Drug Pricing: Takeaways from the MDMA Annual Meeting
    Jun 6, 2025 – 40:21
  • Episode 97 – Drug Pricing: How the Drug Pricing EO Impacts FDA and Overlaps with Grassley-Led Legislation
    May 2, 2025 – 50:18
  • Episode 96 – The Growth Rocketship: Shield AI’s Takeoff Shows What’s Possible in Defensetech
    Apr 30, 2025 – 52:23
  • Episode 95 – Drug Pricing: FDA in the Age of Executive Orders and DOGE
    Mar 12, 2025 – 22:14
  • Episode 94 – Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook
    Feb 25, 2025 – 22:13
  • Episode 93 – EU’s Digital Operational Resilience Act: What You Should Know and How to Stay Compliant
    Jan 16, 2025 – 19:34
  • Episode 92 – UK FinReg Focus Areas in 2025: Sectoral Trends
    Jan 6, 2025 – 29:45
  • Episode 91 – UK FinReg Focus Areas in 2025: Retail Markets
    Jan 6, 2025 – 20:32
  • Episode 90 – UK FinReg Focus Areas in 2025: Wholesale Markets
    Jan 6, 2025 – 23:23
  • Episode 89 – The Growth Rocketship: How BridgeBio’s Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech – Then, Now, and What’s Next?
    Dec 30, 2024 – 47:21
  • Episode 88 – Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?
    Dec 16, 2024 – 33:12
  • Episode 87 – Drug Pricing: What’s In the New CMS Medicaid Final Rule?
    Nov 25, 2024 – 28:38
  • Episode 86 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit
    Oct 18, 2024 – 18:25
  • Episode 85 – Drug Pricing: How The Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry
    Sep 19, 2024 – 21:48
  • Episode 84 – Pro Bono: Shabir Kabiri’s Remarkable Journey from Afghanistan to Asylum in the US
    Aug 20, 2024 – 34:22
  • Episode 83 – Drug Pricing: How Are Payers Responding to the IRA?
    Aug 19, 2024 – 29:16
  • Episode 82 – Drug Pricing: Takeaways from the New Orleans Pricing and Contracting USA Conference
    Jun 21, 2024 – 17:31
  • Episode 81 – Drug Pricing: A Look Behind the Curtain of the New ASP Reporting Website and Other Data Collection Portals
    Jun 13, 2024 – 23:35
  • Episode 80 – Energy & Infrastructure: Why is Energy Tech So Attractive to Venture Capital?
    Jun 10, 2024 – 26:13
  • Episode 79 – Pro Bono: Rewilding the Scottish Highlands Through Forest Restoration
    Apr 16, 2024 – 16:03
  • Episode 78 – UK FinReg Focus Areas in 2024: ESG
    Mar 8, 2024 – 17:12
  • Episode 77 – UK FinReg Focus Areas in 2024: Enforcement Against Individuals
    Mar 5, 2024 – 08:23
  • Episode 76 – UK FinReg Focus Areas in 2024: Regulatory Divergence
    Feb 29, 2024 – 17:49
  • Episode 75 – UK FinReg Focus Areas in 2024: Enforcement Against Firms
    Feb 23, 2024 – 13:24
  • Episode 74 – UK FinReg Focus Areas in 2024: Conduct and Culture
    Feb 19, 2024 – 13:19
  • Episode 73 – UK FinReg Focus Areas in 2024: Artificial Intelligence
    Feb 8, 2024 – 13:54
  • Episode 72 – UK FinReg Focus Areas in 2024: The Edinburgh Reforms
    Feb 2, 2024 – 10:18
  • Episode 71 – Drug Pricing: A Look Ahead at Trends for 2024
    Feb 1, 2024 – 11:48
  • Episode 70 – UK FinReg Focus Areas in 2024: Investment Research
    Jan 31, 2024 – 17:14
  • Episode 69 – UK FinReg Focus Areas in 2024: Retail Markets – Direction of Travel
    Jan 26, 2024 – 13:49
  • Episode 68 – Drug Pricing: Will Agencies Exercise March-In Rights Based on Drug Price?
    Jan 25, 2024 – 13:39
  • Episode 67 – PE Views: The Most Pressing Cybersecurity Considerations For Private Equity
    Jan 23, 2024 – 33:59
  • Episode 66 – UK FinReg Focus Areas in 2024: Primary Markets Reform
    Jan 19, 2024 – 13:54
  • Episode 65 – PE Views: How Can PE Sponsors Promote Transparency and Successful Fund Raise Amid ESG Scrutiny?
    Dec 20, 2023 – 09:51
  • Episode 64 – Energy & Infrastructure: How Can Companies Avoid Greenwashing Allegations and ESG Litigation Risks?
    Dec 18, 2023 – 25:52
  • Episode 63 – M&A Views: How Should Deal Teams Navigate a Global Crackdown on Restrictive Covenants?
    Dec 14, 2023 – 13:57
  • Episode 62 – Has FDA Meaningfully Changed Its Restrictions on Off-Label Communications?
    Dec 13, 2023 – 26:26
  • Episode 61 – Drug Pricing: New OIG Guidance Reaffirms the Seven Elements of an Effective Compliance Program
    Dec 7, 2023 – 12:45
  • Episode 60 – PE Views: Is the CMA’s Focus on Roll-Up Transactions Here to Stay?
    Nov 10, 2023 – 10:28
  • Episode 59 – SCOTUS Update: Perez v. Sturgis Secures a Supreme Court Win for Disability Rights
    Nov 2, 2023 – 37:08
  • Episode 58 – FDI Developments: M&A Security Screening in Europe's Fragmented FDI Landscape
    Oct 24, 2023 – 19:36
  • Episode 57 – Drug Pricing: What Trends Emerged from the 2023 Medicaid Drug Rebate Program Summit?
    Oct 20, 2023 – 12:12
  • Episode 56 – M&A Views: Avoiding Buyer’s Remorse in M&A Deals
    Sep 27, 2023 – 13:25
  • Episode 55 – Insurtech: What Should Startups Do After Receiving FCA Authorization?
    Sep 21, 2023 – 08:37
  • Episode 54 – Drug Pricing: Focus on Best Price — CMS Proposed Rule, Inflation Reduction Act
    Sep 15, 2023 – 13:17
  • Episode 53 – Energy & Infrastructure: Can Sustainable Finance Fuel the Energy Transition?
    Aug 30, 2023 – 18:05
  • Episode 52 – Drug Pricing: Could a Single Reference Price Apply Across a Therapeutic Class?
    Aug 21, 2023 – 11:16
  • Episode 51 – Drug Pricing: Final IRA Price Negotiation Guidance – How CMS Addressed the Part D/B Problem
    Jul 31, 2023 – 10:53
  • Episode 50 – PE Views: Under New Reforms, Is the Customer Always Right?
    Jul 14, 2023 – 12:48
  • Episode 49 – PE Views: Will Greenwashing Rain on the UK PE Parade?
    Jun 20, 2023 – 17:29
Recent Reviews
Disclaimer: The podcast and artwork on this page are property of the podcast owner, and not endorsed by UP.audio.